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Abstract: Introduction: Treatment of rapid ventricular response arterial fibrillation (rapid AF) varies depending on the
decision of the in-charge physician, condition of the patient, availability of the drug, and the treatment protocol
of the hospital. The present study was designed aiming to compare IV digoxin and amiodarone in controlling
the heart rate of patients presenting to emergency department with rapid AF and relative contraindication for
first line drug in this regard. Methods: In the present clinical trial, patients presented to the ED with rapid
AF and relative contraindication for calcium channel blockers and beta-blockers were treated with either IV
amiodarone or IV digoxin and compared regarding success rate and complication using SPSS version 22. P < 0.05
was considered as statistically significant. Results: 84 patients were randomly allocated to either amiodarone
or digoxin treatment groups of 42 (53.6% male). The mean age of the studied patients was 61.8 ± 11.14 years
(38 - 79). No significant difference was present regarding baseline characteristics. The rate of treatment failure
was 21.4% (9 cases) in amiodarone and 59.5% (25 cases) in digoxin groups (p < 0.001). The mean onset of action
was 56.66 ± 39.52 minutes (10 - 180) in amiodarone receivers and 135.38 ± 110.41 minutes (25 - 540) in digoxin
group (p < 0.001). None of the patients showed any adverse outcomes of hypotension, bradycardia, and rhythm
control. Conclusion: Based on the findings of the present study, rapid AF patients with relative contraindication
for calcium channel blockers or beta-blockers who had received amiodarone experienced both higher (about
2 times) treatment success and a more rapid (about 2.5 times) response compared to those who received IV
digoxin.
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1. Introduction
A
rrhythmias are the causes of 12-20% of emergency de-
partment (ED) admissions and one of the most impor-
tant differential diagnoses in patients with complaint
of tachycardia, syncope, or chest pain (1). Atrial fibrillation
(AF) is the most common supraventricular tachyarrhythmia
found in 1-1.5% of the population (2, 3). Its prevalence rate
is less than 0.5% in 40-50 year old population but reaches 5-
15% in 80 year olds (4). In this dysrhythmia, re-entry is seen
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in both atriums and leads to ineffective atrial contraction (5).
Clinical symptoms of AF include vertigo, tachycardia, chest
pain, and fatigue and its risk factors include valvular and
coronary heart diseases, cardiomyopathy, cardiac failure, al-
cohol and caffeine usage, thyrotoxicosis, anxiety, pheochro-
mocytome, emotional stress, hypoxia, and etc. (5, 6). Cal-
cium channel blockers and beta-blockers are the first line of
treatment for this type of dysrhythmia in stable conditions.
Digoxin is the second line due to limitations of using first line
options in critically ill patients and elderly, and in presence of
hypotension, kidney disorder, and heart failure (7). In addi-
tion, IV amiodarone has been used to safely restore the sinus
rhythm and control heart rate in patients with stable hemo-
dynamics and acute atrial tachy-dysrhythmia (7). Therefore,
treatment varies depending on the decision of the in-charge
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physician, patient condition, availability of the drug, and
the treatment protocol of the hospital. Based on the above-
mentioned points, the present study was designed aiming to
compare IV digoxin and amiodarone in controlling the heart
rate of patients presenting to ED with rapid ventricular re-
sponse AF (rapid AF) and relative contraindication for first
line drugs in this regard.
2. Methods
2.1. Study design and setting
In the present clinical trial, patients presented to the ED
of Imam Hossein, and Shohadaye Tajrish Hospitals, Tehran,
Iran, with rapid AF and relative contraindication for calcium
channel blockers and beta-blockers were treated with either
IV amiodarone or IV digoxin and compared regarding suc-
cess rate and complication. The study was approved by the
Ethics Committee of Shahid Beheshti University of Medical
Sciences and registered on Iranian Registry of Clinical Tri-
als (IRCT) under the number IRCT201206047449N2. All pa-
tients filled informed consent forms before being included in
the study. Researchers adhered to all recommendations of
Helsinki protocol and confidentiality of patient information.
2.2. Participants
Rapid AF patients aged between 18 and 80 years old, with
stable vital signs, and any relative contraindication for first
line treatments were included. Diagnosis of dysrhythmia
was made based on 12-lead electrocardiogram by in-charge
emergency physician and confirmed by a cardiologist. Pa-
tients with unstable hemodynamics, chest pain or shortness
of breath, heart failure, and unconfirmed dysrhythmia, as
well as those who had a history of allergy to the drug, un-
derlying kidney or liver diseases, or had used anti-arrhythmic
agents in the past 12 hours, were excluded. Documented or
highly suspected evidence of heart failure and using either
calcium channel blockers or beta-blockers were considered
as the relative contraindications for first line treatment op-
tions. In addition, those who did not give their consent for
participation in the study were not included. Since all pa-
tients would be under supervision for at least 12 hours after
receiving the drug, those who did not want to stay in the hos-
pital for that long were also excluded.
2.3. Intervention:
Using block randomization, the included patients were ran-
domly assigned to either IV amiodarone (Razi Company,
Iran) or IV digoxin (Razi Company, Iran) group. To homog-
enize the groups regarding AF history, classified randomiza-
tion was used. The amiodarone group patients were treated
with 150 mg amiodarone diluted in 100 cc 5% dextrose wa-
ter, intravenously infused during 10 minutes. In case of no
improvement, another 150 mg dose was infused and all pa-
tients received a maintenance dose of 50 mg per hour dur-
ing first 3 hours of treatment. For decreasing the probability
of rhythm control, amiodarone was used with half the dose
needed for rhythm conversion (150 mg instead of 300 mg).
The other group was treated with 1 mg IV digoxin with initial
injection of 0.5 mg and then two 0.25 mg doses in the sec-
ond and fourth hour after intervention. The aim of treatment
was control of heart rate and decreasing it to 80-100 beats per
minute. Heart rate not being controlled with the mentioned
doses was defined as treatment failure. All patients were un-
der constant cardiac, respiratory, and vital signs monitoring.
Due to differences in drug administration, follow-up and side
effects between the two groups, the study could not be per-
formed in a complete double-blind manner. Yet, drug ad-
ministration, treatment evaluation, and data analysis were
done by 3 separate people and the patients were blind to
treatment. In this study, a heart rate over 110 per minute was
defined as a rapid ventricular response.
2.4. Data gathering
For all the studied patients a checklist consisting of demo-
graphic data (age, sex), history of digoxin consumption, time
to treatment, presenting signs and symptoms, history of AF,
and treatment outcomes (heart rate control and probable ad-
verse outcome) was filled. Reduction of heart rate to less than
60 beats per minute, more than 20 mmHg drop in systolic
blood pressure, and rhythm control were considered as ad-
verse outcomes. Data gathering was done by a senior emer-
gency medicine resident.
2.5. Statistical Analysis
Based on previous studies, treatment success was 31
3. Results
3.1. Baseline characteristics
84 patients were randomly allocated to either amiodarone or
digoxin treatment groups of 42 (53.6% male). The mean age
of the studied patients was 61.8 ± 11.14 years (38 - 79). Ta-
ble 1 shows the baseline characteristics of the patients. No
significant difference was present regarding underlying dis-
eases (p = 0.616), history of digoxin consumption (p = 0.641)
and type of presentation on admission to ED (p = 0.189).
3.2. Outcome
The rate of treatment failure was 21.4% (9 cases) in amio-
darone and 59.5% (25 cases) in digoxin groups (p < 0.001).
The mean onset of action was 56.66 ± 39.52 minutes (10 -
180) in amiodarone receivers and 135.38 ± 110.41 minutes
(25 - 540) in digoxin group (p < 0.001). None of the patients
showed any adverse outcomes of hypotension, bradycardia,
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Table 1: Baseline characteristics of the studied patients
Variable Amiodarone Digoxin P
Age (years) 63.73 ± 11.06 59.88 ± 11.02 0.113
Sex
Male 23 (54.76) 22 (52.38) 0.50
Female 19 (45.23) 20 (47.61)
Presenting sign and symptom
Dyspnea 20 (47.6) 14 (33.3)
Chest pain 13 (30.9) 9 (21.4)
Palpitation 16 (38.1) 12 (28.5) 0.189
Dizziness 1 (2.3) 2 (4.7)
Others 2 (4.7) 10 (23.8)
History of digoxin consumption
Yes 30 (71.4) 27 (64.3) 0.641
No 12 (28.6) 15 (35.7)
Data were presented as mean ± standard deviation or frequency and percentage.
and rhythm control.
4. Discussion
Based on the findings of the present study, rapid AF patients
with relative contraindication for calcium channel blockers
or beta-blockers who had received amiodarone experienced
both higher (about 2 times) treatment success and a more
rapid (about 2.5 times) response compared to those who re-
ceived IV digoxin. Currently, controlling heart rate is deemed
more important than rhythm control in treating AF patients,
especially in old people with non-acute symptoms (1). In
2008 Kirsten et al. discovered that the results of rate and
rhythm control do not show significant difference regarding
cardiovascular side effects, and prevalence of mortality, car-
diac arrest, and cardiac failure (9). The effect of IV amio-
darone in controlling the rate has been proved in most condi-
tions such as cardiomyopathy and coronary artery and valvu-
lar diseases (2). Cochrane et al. compared the effects of
amiodarone and digoxin in patients after cardiac surgery and
found that administration of amiodarone as IV infusion af-
ter cardiac surgery is safe and as effective as digoxin, and
decrease in rate is more obvious in amiodarone treated pa-
tients (2). In a study by Del Arco et al. in 2005, control-
ling the rate of the patients with amiodarone was more effec-
tive than digoxin (10). In our study also, response to treat-
ment was higher in amiodarone treated group compared
to digoxin group and treatment failure risk in amiodarone
group was about half the digoxin group. Treatment failure
in atrial tachy-dysrhythmia patients may have different rea-
sons. Some believe that increase in sympathetic tone of
the patients is the reason for not responding to some anti-
arrhythmia drugs (7). In Heny et al. study, digoxin was inef-
fective in patients with increased sympathetic tone. In con-
trast, IV amiodarone was very effective and had high hemo-
dynamic stability in critically ill patients (7). IV amiodarone
has the ability to block calcium and sodium channels in ad-
dition to anti-androgenic characteristics. Its anti-androgenic
characteristics increase due to its ability to decrease nor-
epinephrine, and can therefore be more effective in cases of
increased sympathetic tone. Based on the afore-mentioned
points, it seems that between amiodarone and IV digoxin,
amiodarone is a better choice for controlling the rate of AF
patients who had relative contraindication for first line drugs
of choice, in emergency settings. Yet, generalization of the
findings has some limitations due to inability to double blind
the study and small sample size.
5. Conclusion
Based on the findings of the present study, rapid AF patients
with relative contraindication for calcium channel blockers
or beta-blockers who had received amiodarone experienced
both higher (about 2 times) treatment success and a more
rapid (about 2.5 times) response compared to those who re-
ceived IV digoxin.
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